Publications by authors named "M Retz"
Article Synopsis
- The IMvigor210 trial assessed the long-term efficacy and safety of atezolizumab, an anti-PD-L1 therapy, in patients with advanced metastatic urothelial carcinoma (UC), showing manageable toxicity.
- The trial involved two cohorts: untreated UC patients ineligible for cisplatin-based chemotherapy and those previously treated with platinum-based chemotherapy, with a median follow-up of up to 96.4 months.
- Results indicated objective response rates of 23.5% in untreated patients and 16.5% in previously treated patients, with median overall survival of 16.3 months and 7.9 months, respectively, along with a notable percentage of patients experiencing grade 3/4 adverse events. *
Background: Patients with locally advanced or metastatic urothelial carcinoma face a poor prognosis. Standard first-line treatment involves platinum-based combinations followed by avelumab maintenance therapy. Follow-up therapies include enfortumab vedotin, vinflunine, and taxanes.
View Article and Find Full Text PDFThe risk of recurrence in patients with muscle invasive bladder cancer (MIBC) after radical cystectomy depends on the pathological tumor stage. In particular, patients with lymph node metastasis (pN+), locally advanced (≥pT3), or residual muscle invasive tumor despite neoadjuvant chemotherapy are at high risk. Currently, the importance of adjuvant therapy with immune checkpoint inhibitors is increasing in the context of perioperative systemic therapeutic concepts.
View Article and Find Full Text PDFArticle Synopsis
- Atezolizumab was assessed for its safety in a diverse group of patients with pretreated urinary tract carcinoma (UTC) in the SAUL study, which included those typically excluded from clinical trials.
- The study involved 1004 patients and found that 68 patients continued treatment for over 4 years, with 16% experiencing serious treatment-related adverse events.
- Long-term results show a median overall survival of 8.6 months, with 14% of patients surviving more than 4 years, indicating the drug's potential benefits in real-world settings with complex patient profiles.
Background: Limited responses have been observed in patients treated with enzalutamide after disease progression on abiraterone for metastatic castration-resistant prostate cancer (mCRPC), but androgen receptor signaling impacts T-cell function.
Objective: To evaluate the efficacy and safety of pembrolizumab plus enzalutamide in mCRPC.
Design, Setting, And Participants: Patients in cohort C of the phase 1b/2 KEYNOTE-365 study, who received ≥4 wk of treatment with abiraterone acetate in the prechemotherapy mCRPC state and experienced treatment failure or became drug-intolerant, were included.